Yuet‐Kin Leung
Associate Professor
Also affiliated: Taiwan Semiconductor Manufacturing Company (United States) (2006); Hong Kong Institute of Vocational Education (2007); University of Massachusetts Chan Medical School (2003–2006); Chinese University of Hong Kong (1998–2022); The University of Western Australia (2012–2017); National Institute for Occupational Safety and Health (2015); Vanderbilt University (2002); Cincinnati Health Department (2011–2019); University at Albany, State University of New York (2011); Singapore Institute of Manufacturing Technology (2002); Central Arkansas Veterans Healthcare System (2020–2024); Center for Human Genetics (2013–2015); Baxter (France) (2015); Taiwan Semiconductor Manufacturing Company (Taiwan) (2003–2019); Applied Decision Science (United States) (2017); Women and Infants Research Foundation (2017); Winthrop Rockefeller Foundation (2023–2026); Society of Environmental Toxicology and Chemistry (2018); Environmental Health (2007); Cancer Genetics (United States) (2013); Oncology Hematology Care (2015); Arkansas Department of Agriculture (2026); Stanford SystemX Alliance (1996–2002); Swinburne University of Technology (1994–1999); University of Cincinnati (2006–2026); University of Cincinnati Medical Center (2006–2026); Stanford University (1996–1998); Baxter (United States) (2015)
Faculty Researcher
Pharmacology & Toxicology, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Yuet‐Kin Leung investigates the molecular mechanisms underlying disease, with a focus on cancer and the impact of environmental exposures on human health. His laboratory has explored the discovery of novel inhibitors for specific genetic mutations in acute myeloid leukemia, including FLT3 and its resistant mutants.
Leung's research also extends to the field of epigenetics, examining how environmental chemicals can lead to alterations in DNA methylation in placental and cord blood cells. He has studied the role of specific nuclear receptors, such as NR2E3, in augmenting signaling pathways implicated in hepatocellular carcinoma through epigenetic dysregulation. Furthermore, his work has investigated the intergenerational effects of paternal exposure to environmental toxins like arsenic on sperm quality and potential impacts on offspring.
His scholarship is evidenced by a significant publication record, with 142 total publications and over 5,450 citations, contributing to an h-index of 40. Leung has also secured federal funding, including a $468,131 grant from the NIH/National Institute of Environmental Health Sciences as a Co-PI for research on RNA modifications by paternal exposure to arsenic and intergenerational effects on sperm quality. He is recognized as a highly cited researcher and collaborates with colleagues at the University of Arkansas for Medical Sciences.
Metrics
- h-index: 40
- Publications: 142
- Citations: 5,489
Selected Publications
-
Service Year-Dependent Disruption of Reproductive Hormones and Altered DNA Methylation in Male Firefighters (2026)
-
A transcriptomic-driven segmentation and cell simulation framework for high-resolution spatial transcriptomics and cell-cell communication (2026)
-
CD5L promotes efferocytosis and resolution of retinal ischemic injury (2026)
-
Epigenetic signatures of maternal-fetal health: insights from cord blood and placenta (2025)
-
Global metabolomic alterations associated with endocrine-disrupting chemicals among pregnant individuals and newborns (2025)
-
Proteomic Analysis of Aqueous Humor in Central Retinal Artery Occlusion: Unveiling Novel Insights Into Disease Pathophysiology (2024)
-
Endocrine-Disrupting Chemicals: A Looming Threat to Current and Future Generations (2024)
-
Gestational exposure to environmental chemicals and epigenetic alterations in the placenta and cord blood mononuclear cells (2024)
-
The Loss of an Orphan Nuclear Receptor NR2E3 Augments Wnt/β‐catenin Signaling via Epigenetic Dysregulation that Enhances Sp1‐β catenin‐p300 Interactions in Hepatocellular Carcinoma (2024)
-
Abstract 3011: The loss of an orphan nuclear receptor NR2E3 augments Wnt/β-Catenin signaling via epigenetic dysregulation that links to the Sp1-β catenin-p300 interactions in hepatocellular carcinoma (2024)
-
Abstract 6282: Novel androgen related gene network in prostate cancer cell model (2024)
-
Maternal and newborn metabolomic changes associated with urinary polycyclic aromatic hydrocarbon metabolite concentrations at delivery: an untargeted approach (2023)
-
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L (2023)
-
Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care (2023)
-
N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants (2023)
Federal Grants 1 $468,131 total
RNA modifications by paternal exposure to arsenic and intergenerational effects on sperm quality
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- DNA methylation markers associated with exposure and adverse health outcomes in Veterans exposed to airborne hazards from open burn pits DOD Co-Investigator
- NSF, RII Track-2 FEC: Facilitating Ubiquitous Technology Utilizing Resilient Eco-friendly Sensors (FUTURE Sensors) National Science Foundation via Louisiana Tech University Co-Investigator
Collaboration Network
Top Collaborators
- Gestational exposure to environmental chemicals and epigenetic alterations in the placenta and cord blood mononuclear cells
- The Loss of an Orphan Nuclear Receptor NR2E3 Augments Wnt/β‐catenin Signaling via Epigenetic Dysregulation that Enhances Sp1‐β catenin‐p300 Interactions in Hepatocellular Carcinoma
- Three-Generation Study of Male Rats Gestationally Exposed to High Butterfat and Bisphenol A: Impaired Spermatogenesis, Penetrance with Reduced Severity
- Maternal and newborn metabolomic changes associated with urinary polycyclic aromatic hydrocarbon metabolite concentrations at delivery: an untargeted approach
- The androgen receptor inhibits transcription of GPER1 by preventing Sp1 and Sp3 from binding to the promoters in prostate cancer cells
Showing 5 of 11 shared publications
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
Showing 5 of 6 shared publications
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
- An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
- N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants
- Gestational exposure to environmental chemicals and epigenetic alterations in the placenta and cord blood mononuclear cells
- Maternal and newborn metabolomic changes associated with urinary polycyclic aromatic hydrocarbon metabolite concentrations at delivery: an untargeted approach
- Global metabolomic alterations associated with endocrine-disrupting chemicals among pregnant individuals and newborns
- Epigenetic signatures of maternal-fetal health: insights from cord blood and placenta
- Gestational exposure to environmental chemicals and epigenetic alterations in the placenta and cord blood mononuclear cells
- Maternal and newborn metabolomic changes associated with urinary polycyclic aromatic hydrocarbon metabolite concentrations at delivery: an untargeted approach
- Global metabolomic alterations associated with endocrine-disrupting chemicals among pregnant individuals and newborns
- Epigenetic signatures of maternal-fetal health: insights from cord blood and placenta
- Gestational exposure to environmental chemicals and epigenetic alterations in the placenta and cord blood mononuclear cells
- Maternal and newborn metabolomic changes associated with urinary polycyclic aromatic hydrocarbon metabolite concentrations at delivery: an untargeted approach
- Global metabolomic alterations associated with endocrine-disrupting chemicals among pregnant individuals and newborns
- Epigenetic signatures of maternal-fetal health: insights from cord blood and placenta
- Gestational exposure to environmental chemicals and epigenetic alterations in the placenta and cord blood mononuclear cells
- Maternal and newborn metabolomic changes associated with urinary polycyclic aromatic hydrocarbon metabolite concentrations at delivery: an untargeted approach
- Global metabolomic alterations associated with endocrine-disrupting chemicals among pregnant individuals and newborns
- Epigenetic signatures of maternal-fetal health: insights from cord blood and placenta
- Gestational exposure to environmental chemicals and epigenetic alterations in the placenta and cord blood mononuclear cells
- Maternal and newborn metabolomic changes associated with urinary polycyclic aromatic hydrocarbon metabolite concentrations at delivery: an untargeted approach
- Global metabolomic alterations associated with endocrine-disrupting chemicals among pregnant individuals and newborns
- Epigenetic signatures of maternal-fetal health: insights from cord blood and placenta
- Gestational exposure to environmental chemicals and epigenetic alterations in the placenta and cord blood mononuclear cells
- Maternal and newborn metabolomic changes associated with urinary polycyclic aromatic hydrocarbon metabolite concentrations at delivery: an untargeted approach
- Global metabolomic alterations associated with endocrine-disrupting chemicals among pregnant individuals and newborns
- Epigenetic signatures of maternal-fetal health: insights from cord blood and placenta
- Gestational exposure to environmental chemicals and epigenetic alterations in the placenta and cord blood mononuclear cells
- Maternal and newborn metabolomic changes associated with urinary polycyclic aromatic hydrocarbon metabolite concentrations at delivery: an untargeted approach
- Global metabolomic alterations associated with endocrine-disrupting chemicals among pregnant individuals and newborns
- Epigenetic signatures of maternal-fetal health: insights from cord blood and placenta
- Gestational exposure to environmental chemicals and epigenetic alterations in the placenta and cord blood mononuclear cells
- Maternal and newborn metabolomic changes associated with urinary polycyclic aromatic hydrocarbon metabolite concentrations at delivery: an untargeted approach
- Global metabolomic alterations associated with endocrine-disrupting chemicals among pregnant individuals and newborns
- Epigenetic signatures of maternal-fetal health: insights from cord blood and placenta
Similar Researchers
Based on overlapping research topics